𝔖 Bobbio Scriptorium
✦   LIBER   ✦

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

✍ Scribed by Richman, S. D.; Seymour, M. T.; Chambers, P.; Elliott, F.; Daly, C. L.; Meade, A. M.; Taylor, G.; Barrett, J. H.; Quirke, P.


Book ID
119973300
Publisher
American Society of Clinical Oncology
Year
2009
Tongue
English
Weight
164 KB
Volume
27
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.